Aurinia Pharmaceuticals (AUPH) 12 Aug 202020 Q2 Earnings call transcript

Greetings, and welcome to the Aurinia Pharmaceuticals Second Quarter 2020 Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dr. Investor of Head Schulman, Relations. Glenn may Thank you, you begin.

everyone. you, second Aurinia's and afternoon, Jessie, good Welcome quarter to Thank XXXX conference call.

the Greenleaf, our Dr. Neil on are Miller, our Max me call Chief Officer; Aurinia Joe the Joining and Financial team Colao; Mr. Mr. Peter commercial Medical President chief CEO; Solomons, Chief which and officer, Mr. our quarter from today press statement package Aurinia. at financial XXXX results, filed This with associated financial afternoon via on release the we and are both www.auriniapharma.com and SEC. of issued website the second available our X-K detailing Officer,

Before be completion transcribed also today's jumping may brief call available approximately the consent Aurinia. prior and of Aurinia's from that the webcast like today's being note website, team, the on two call live or the hours It I'd obtained today's into some Aurinia. of Please is reproduced that Investor without everyone is will to recorded, replay remind call. of Relations content property remarks from written not a be after

our make out statements significant approval, e-mail differ a risks of me, free our results may feel and call, to actual to please of expectations. current course may statements materially. ir@auriniapharma.com. forward-looking are reach the subject we Also Glenn at Schulman, on note, For based These number during this via forward-looking to and uncertainties,

with and Securities business, authorities our on to Exchange discussion a the X-K refer most affect Securities with law, based of of our during today, For and Also, August please Tuesday, filings XX, update as are please and as by available Except we that we current and are of Canadian factors results this currently call assume no that disclosure note date. to today's any statements information us. obligation U.S. required the file Commission. such financial press recent in future to made Form as XXXX, the all reports statements upon today's of release, could

results. So, to I'm our financial Peter? the busy all everyone those remarks Neil – turn remarks that, summertime, it turn for open the pipeline, over for I let it regarding quick Peter brief and Q&A. from also preparation is commercial opening we'll so and know a voclosporin Joe Max updates in give for some after we'll quick up After and President going to of Peter Aurinia's to call our CEO. and that, With me Greenleaf, over and

second with of all company Hey, review to thanks our thank Glenn. to us on want And quarter I the taking the behalf results. time you for

XXXX we Glenn issued along second few As months. past operational our from quarter mentioned, with results highlights this afternoon the

this for nephritis. of on to patients were both both we failure. our their be getting and and the doing, pleased with This long healthcare launching community As has and life-threatening outcomes proud of significant team burdens engagement and relative too to patients hopefully potentially therapy our Even nephritis progress of to progression prevention no for make chance work voclosporin the approved towards kidney the the for approved creates awareness SLE, our the underserved incredibly nephritis options real a the making been lupus with specific of to lupus treatment we're a to sufferers difference potentially for nephritis suffering goal first disease management and a in significant system. for incredibly are FDA ever lupus Lupus improve and of with such community. and community from

launching to needless will far a operational for voclosporin highlights, year our on more even so before near to up focus your busy very And the and to very, a things afternoon turning successfully as few future. we ramping minutes been recap has we us on say, moving potentially XXXX spend so in provide a are the So over to this just quick call questions.

AURORA trial been the since the ready significant December last have the with of from data nephritis progress the we have We of be order treatment lupus the voclosporin rapidly and turned for end organization XXXX. and by launch in card pivotal to made responsibly growing

Our clinical early filing the with with package days besting goal earlier getting continue had NDA their past U.S. for of filing we and our teams execution our voclosporin internal XX than regulatory nearly agency by excellent into this anticipated. even the FDA the the May

date voclosporin XXXX. action ago, PDUFA accepted Administration, a our - Drug the weeks by January date we Food was and announced As NDA it granted XX, for and given U.S. was a of review few filing priority

operations, fully leadership team our an phenotype with track as Adcom strongly which our during the and course out view positive with the distributed This hasn't signal, for commercial we stopped the a In to building addition, been patients advisory launch get commercial year. right of the prior earlier are individuals this recruitment entirely successful the swiftly voclosporin need the industry. review place this efforts in in to function aligned our of in last united and been several internal into realized fortify capital potential view received in are completed intend to but of for stated rapid year-end. working to experienced having it has sheet voclosporin. revenue records to have almost gross nature plans. months internally and balance to virtual our $XXX current We and any a important May. for force In their drive and gratifying With or our sales team over we we $XXX the was partnerships and the our action in on team development do in process. put robust The is ready high-performing on since preparations move the approval. not efficiently they in on make that ex-U.S. with recruiting that years communication I execute Despite an has trained million we've cash meeting actively on-boarded, by specialist after mention can capital date. on spoke nearly other thought committee anticipate from which nationally commercial the follow-on many also parallel gathered that of based the successfully reserves Agency, end, agency To change their talented or brought FDA the non-dilutive in-licensing offering, the the possible provide position an holding proceeds their from now of next million we a world-class excluding

the with ongoing additional programs. NDA overview, voclosporin to ongoing turn call Neil Neil? Dr. and regarding process add Solomons I'll development the that color the So over to brief now review

and afternoon Thanks, everyone. good Peter

time and regulatory groups. entire exciting clinical Peter As for the been mentioned, very it busy has a and

be interactions that the the the on patients lupus of team for worked years truly my Given a through suffering are progress from has advancing of make humbled the regulatory potential our care that to recent number these we've on quite the therapy difference FDA. patients. standard in we cusp for the on are made delivering nephritis, And can of we gratified with also

and also date the not July momentum the XX was letter XXXX. XX a accept the the maintained news, NDA filed PDUFA but review is January the the the and internal for pandemic Review of The in granted regulatory Aurinia As COVID-XX date through only reminder, Priority estimates. our received approximately also but voclosporin the our for validate days scheduled FDA did team with filing ahead FDA with welcome it

mentioned the well month, application. the and letter anticipate response they FDA last announced earlier, also ongoing with a to we Meeting manufacturing XX the Agency recently respect to Peter date. as scheduling do the take label, PDUFA review review this indicated that continues an proposed Agency Therefore said, regarding Advisory to mind received period. as we visits to in change though prepare That an not Committee need and their as with right their scheduling outcome [ph] retains throughout their As will as host outcome clinical team the the the during and continues routine and activities the period other process site an place [indiscernible] for

could voclosporin We against. are conditions working also kidney additional characterize to we evaluate that diligently proteinuric

Phase to combining that indications will have for XX-week Test weeks. recently provide Switching of this This VOS, The endpoints deep at months, vehicle. patient we improvement organization Over ranging doses our three enrollments the the primary we an and secondary of evaluating Schirmer announce were few weeks, forward the on the complete updates pleased dry is X/X XX from study. endpoints gears eye, compared VOS, across internal is or later study to solution study dose ophthalmic Tear next completed we in and X.XX% greater the at AUDREY the thermometers we dive to voclosporin of look four to with insights X.X, year. X.X, [indiscernible] program in

operations, enrollment quarter of on report year. first developments complete, of corneal will staining as evaluating we as in are teams X/X also the to pass before of fronts, that of eye. steps our call biostats clinical over work trial results clinical clinical trial we FDA our the initiation a the determine addition, results track dry VOS. with this brief to the have guide and incredible The expect during With on thanks update improving and the the of In development Phase regulatory potential and to planned available topline Max? we this are next symptoms interactions Max. results second program the after pivotal and I'll are in well the to With

we're the of take time. minutes highlight good voclosporin and to for progress Neil, that launch approval Thanks to couple making and lupus nephritis. becoming Thanks taking in the afternoon for ready potential everyone. I a want

the mentioned the board, team. and/or has earlier join individuals the especially and/or experience in member most gratifying recruit and nephrology the grown relevant organization it of nephrology our to the the least for that over experience has years they course we XX of me team experience. individuals Each field commercial tenured exponentially breadth industry. see attracted our is we've rheumatology at the As as of depth of rheumatology with and XXXX peter of Across

to step care treatment a company and step of the to holding how rare consequences, support failure. receive the treatment aim responsibility way in patients patient we're our specialized, to to will journey, diagnosis avoid experts to LN others. and building premier such to support At to We a from treatment opportunity on every patient be with step surrounded center first support to The feel potentially the as prescribed. the this ourselves optimal trained serve LN of miss we from is As remaining journey, at the directly, every that the the disease a efforts decision, access we team. potentially journey different in can treatment disease to LN standards dedicated patients LN at navigating as reimbursement be highly understand and kidney highest commercial a to resources and community by of every pharmaceutical of

last call, and the introduced expanded we During team. our leadership commercial experienced highly

access, across count, leadership great progress patient more professional made operations. sales on our positions. have strong of than At We our building open we've and for applicants last training relations, in had advocacy, foundation services, XXXX

XXX We we've have and hired three XXXX interviewed than than more last months. in the more candidates

we've hiring our now for As almost of completed roles. customer all facing

said, The commercial launch so. being and Peter ready customers. on track focused engaging organization and also come we're PDUFA well we online do appropriately As date are to before to on our continues

operations, We burden occasion the over have recognize of finalizing on We're and Joe? that of pass to we're infrastructure for value for LN our and launch engagement, of also and our the to enhanced the With patients. financial aims the they building well started highest that with expectations now to plans. now track customer engage recap therapy customers. meet it payers ensure Joe to I'll compliance efforts results. and review, our patients our for We've of

you, Thank Max.

XXXX the $XX.X million XX, XX, $XXX.X for $XX.X June March in at XXXX compared term the cash, of Net to XXXX operating year. at had was $XXX activities cash cash to at million June same and quarter ended million last the XX, investments short financial Aurinia December in front, period XXXX. XX, million On second and equivalents $XXX.X used compared

and $XX.X warrants outstanding and quarter month not million $X.XX XXXX will of be result of warrants estimated million for for the $XXX,XXX reflecting $XX.X million expense As XXXX. by administration to compensation June on quarter warrant June the Non-cash we or a XX, or The the of corporate, of for commercial the corporate, of expire trial, liability loss in to a quarter per outlay XXXX. to fair for reported ended XXXX XX, and quarter the Phase XX, liabilities the loss in million estimated second quarter increase of personnel same cash value the the the the of on to offset share the of the in June June has quarter the continued AUDREY second the derivative XXXX of the development $X.X to million in $X.XX comparable the number release The loss exercise fair the warrant stock ended Corporate estimated fair June expenses $XX.X voclosporin of team derivative trial for second net period increase R&D price. significant the the for share per quarter $XX.X this to consolidated XXXX. period build compared in included an income to expenses share support XX, the and compared taxes the the medical the XX, forfeiture and granted compensation any value of ended in for before $X.X to XXXX the number increase $XX.X this of expansion press activities, December costs a second in for personnel in for common a AURORA company's of of affairs ultimately stock an hiring the the increased common AURORA significant ended ended in into afternoons consolidated administration detailed June reflected June of XXXX. was for ended XX, the increased the for value The compared into period a XXXX. compared the net XXXX XXXX to in of XX, reflected overall change in the the in for R&D trial ended by million million also $X.X $XX.X quarter loss the costs ended an of XX, expenses NDA business ended of X/X XXXX to June consulting related an organization and XX, compared options decreased XXXX $X.X second for Noncash supporting XXXX XX, in the XXXX. increase completed. million we compensation second preparation three quarter options second partially primarily million $XX.X reflecting quarter price. costs, the share expenses ongoing warrant development professional fees, and trial and second expense for million the VOS decrease the quarter increased higher The XXXX. to to submission company's value of liabilities now fair the comparable extension launch compared second The related of higher the on expansion June the second increase been of X to costs second fair XXXX derivative compared value $XXX,XXX due reduction out derivative stock stock liabilities will warrant team, also million to an business as charged and lower and the charged in $X XXXX million granted and hiring insurance eliminated

on which capital $XXX supply this commercial review support and and the financial drug believe investments cash, company's completing remarks. to commercial and developing for July XX, plans, packaging closing that public XXXX. Peter? research include fund back the I'll resources Peter and With short-term working million ANDA pass cash XXXX. our totaled our FDA, pre which of our needs. and programs, operating recently manufacturing equivalents our the activities, some XX, offering, fund it completed conducting launch that to we corporate approximately current ongoing submission and $XXX July at We closed raise Following sufficient have million following to The

Joe. thanks Hey,

attract this productive echo pride in our the for mission so overall Aurinia. opening high at to here ability many really the company to professionals, and Q&A, our a as me exciting quality at up Let before us time

on We exploratory underscored last confirmatory syndrome at the deepened of staff would a a voclosporin, their upon investments the disease to a the the engagement lead equivalents eye mission importance voclosporin. the dry feel data an potentially you impressing new which year launch regards voclosporin of lives. million which anticipated your of execution pivotal I feeling attention pending people to amply cash questions. the our for here X With of team new and the to Phase and and for of to of build with program Our $XXX and discussions outstanding produced end funded fourth lupus driving the has all these of care and With VOS. want the today their been AUDREY community urgency will results quarter continued sheet to are balance the support approximately to nephritis short-term regulatory study it's delivering and strong changing launch importance standard cash, in on of to we've that course for are thank answer deliver pipeline. and we our your all of I the July, and our

So for that operator, open with the Q&A session. please up

Cantor you. from Thank of first the Alethia line with Young Our Fitzgerald. with proceed question comes question. your Please Instructions] [Operator

at where who to I kind for to think and of just about AURORA Hey kind about some and lot understand that of a on I clinical give wanted you continued kind how subgroups are taking – real know have be like you making. kind work and and been race, world these, congrats the then or little that guys, launch the physicians kind progress trying them, little dose guide will bit whether through the of and during measure guys about thanks that some talk world, you real the thinking is the by most, talk some of focusing the but of a of that And kind are therapy? looking prespecified any trial, in how – know the on mean, study kind for happened my was adjustments the I'm I One people can obviously be I you bit in might of the might of managing it might of of the questions the just guess benefit and or gender, a other just of you the in thanks?

their but be it also guide a our so let think we've on whether I'm to then as great from me that's I input a common give you try of first question, little something an Max and of down going the question is it feel how of and able about so to practice. to to a terms going some update been physicians pretty terms real-world of is to able to I bit doing going and come going in to we're pass I is physicians lot we're be adjustments. we thinking medicine the Yes, start and in preparation this this he monitoring can get think to might how standpoint that to into adjustments comfortable what incorporate the mean comes in how commercial dose of population, label Neil sort these practice on are to across a which

what to trials a of at So in be and could work that to best the try on our point patients aspirational terms drug I in the be who today, strategy as suited the populations drug. we've on beauty I been best capture here said of think on an broad the and challenge the patient is terms think the going we post in think had physicians start their shouldn't of could pretty we data, where be And we're trial. doing I incorporating really

into patients goal they really drug current mix challenge on broad little about the of some the may bit deserve little over incorporated maybe depending the drug you to as he to additional both a, give care to bit it the pertains patients. course the what and results of standard yourself. two a just a and not And talk done that be turn Max our want little I the add question more need flow and would of to that? which is drug modeling, positioning, We to of the just doing may et and failure a seen. worker be of Max was to beneficial, cetera. we're we’ve the sort our to get for benefit label dig Colao on to unmute it trial try patients on you want Max trial Our as bit of group of our a our and patients a a do can preview

for I your Yes, got question. no, you, thanks and thanks Peter

complications failure on As leads is you of LN one and damage, serious irreversible it SLE and of immune most standard even know to is death. kidney it that left you know, if focuses kidney suppression. And untreated, the of care the

outcomes and LN replacement care. compared progress trial voclosporin the of a X We in good with of the fact to unsatisfactory due Phase regimen to that that standard need these of the that kidney relative to Our therapy. subset are standard know patients failure care long-term

So, can name voclosporin tremendous we we potential as think the reset we to the LN. prevent irreversible loss first the is, for think the possibly of Peter about a said, that the ourselves term intervention disease damage. course and outcomes about kidney we we and that see long early the as this as benefit patient. And see change and care We're excited an very of with line for for standard opportunity our

matching one and some know these Glaxo me works it like I about I follow-up? up tends work Thanks. ask compound, your to of quick perspective Can it. on slower, have Got the, different kind Some of asked wanted voclosporin. to compounds of just people but get I the

like are easy, there about that process Yes, going out review the just investigation through being talking or under it's on Benlysta. currently other therapies

the clinical months happens too. they're, slightly response have get seen other Nephrons matters, patients disease take day, quickly know, put investigational appear to we've of far the of mantra Your think the numbers date we think to at But different. the with account affected take most there. have that to that rapidity longer to product we've are time there. And benefits, different, think all I trials and studies there's you into drug, And The the so we a that I of drugs obviously, the I to of see one done in is and multiple this and how that that internal end treatment quickly are we're time of be, to the their to to the as we physicians to and patients. types have the six Neil, impacted want as outcomes believe going to but control have an anything we going how to and to early critically is not be that? is of into as important we're you add just

mean, from effect, I would the at drug think that is XX to I about months. and so presented tolerated, two similar years although defined are No, ours Alethia six well well takeaway they months the is Benlysta appear from their the far is least response certainly rates or it data treatment have at

think, compound, talk data I that amounts measures have also, the So trials, of caveat limited about as we But we used a and there. magnitude that is there's compound well on they've that and do our in particular in effect or caution of does. different detail outcome can their what

thank you. Great,

Alethia. Thanks,

Thank you.

[ph] next Our of comes with with Gordonhoff question. Cowen. your line proceed from question Please Georgie the

my Thank you, guys taking for question.

So do follow-up with peers [ph] clarity the progress month's review, and you pricing? any commercialization. could priority on then a your have if given comment yes, I on first we negotiation on And the have potential and six

call of dollars of of in as where said a a previous going prices we've year. to taken I year There's But and Yes, once in determined and in is it's you Max label mean did to final could in and do RA in of team, And similar of launch right have fairly to can, when the in value come the areas if the drugs doing be good get at of include say of as call a Max work I'll even least that a But both drug from went to what the of day, that right a same engaging Biologics we much next to, bit introductions been remains here a elasticity get and last wide as to to here the looks and and bit have Phase as in I there speak. some little for label to that's the label you to a disease the small $XX,XXX have have areas, prices payers see been I course, from lot look similar over our there's his indications physicians we until that outset. and I troll thousands terms that the the access like. size, the done price ensuring of calls, approval it sort were and, from the research like of at miss, if idea there negotiations, and high looked look it's all think happening range. somewhere a up $XX,XXX go sit of his what really the work actually Max anything like, we're product song X, a quite through with sort that then in by jump for like would we hundreds a launched we to feel seem a molecules. year price know, we GI said pricing, the going not that $XX,XXX those there the burden, think took out probably we of companies like we're of the anywhere out to everything round end post the an So and at in of ease and and supporting a finally fat we and what comments past get out I I very it we by And label of free. MS said the that, of if price making today a proposition voclosporin, we've grouping already and comments payers that $XX,XXX XX areas, patient, population and mostly disease, way autoimmune range calls we're

to that are similar analysts how you today. So that, want I've if competing in our a think to I hitting products some of that of today other guided is and investors you know, of benchmark just areas other median the sorts where of use sort

take that could an the I competitor lupus SLE. have infusion IV consideration for to think we studied product, coming market a for in they're we into formulation right nephritis. was and injectable Benlysta That also while have as now into

we weight, and at cetera, or the like is we average may if high changes, annual Benlysta. there range weight average look probably So, low for but look $XX,XXX what mid try what would just SLE an look to, at year patient basis, XXs, to we infusion the, the think patient nephritis on et you're based at be lupus looking their a some getting a just has

mind. a So we in to I have keep think at. we that look It's beacon can

did from I've payers talking just overall label our to be end Everything proposition. value of else given context we're We're takeaways, I determined key the work. contexts will sort to around you other be drug. Max, at looking the At is on? starting going what So access our we aggressively. missed is separate by today pricing and which there that's out do to community in the the day of

Yes, thanks, Peter.

at potential a that standard payers the superior burden from payers clinical profile the recognize and payers You the we're damage, it so to results add seriousness we've been heard in our showing which and economic kidney far, the in feedback efficacy of our could can I of irreversible that's pretty failure but to kidney care, appreciate clinical positive heard to And a engagement, early demonstrating to we also comparable. associated while ESRD. prevent the and lead appreciate safety found covered comprehensively. pretty LN standpoint. We've the has payer payer

the been far So feedback positive. has

Thank labor very that guess, of clarity discussions expect we have This to be any you. And date? sort or PDUFA was expect I and helpful. prior communication on the Advisory just the Meeting, do no you Committee do labeling standalone assuming FDA, any there'll to with any

at we course, basis. our receive with we've reported. get, we Agency something was correspondence passed formal XX And, everything not the we confirmatory, day Well, a be dialogue example, as for and of the it from agency ongoing of on just that's did will day communicated it day-to-day XX. And that's already

would entire meaningful I of directly think indirectly there the of elements go throughout would him what here, around a that the in something you there. comments till the the in here, would for all Neil ongoing comments changes nothing an add it's approval. be then up mix But And it's add label label I, there's as process. Neil in terms and itself his to that way process as be support some asked that will are will and for I that? in what So what through first would had and

discussions to I review no, of brings on something The go consequent labels and down. parallel the think in most comes Yes, review is that's it. point FDA covered about in the a the seem you what for general with and that's discussion the

That's time. great. much. much Thanks Thank you for so giving so

Thanks.

Thank you.

Please Wainwright. H.C. Ed line of the next with comes question Arce your Our question. with proceed from

taking for a Hi, I here. my couple everyone. have Thanks questions.

First, medical team teams, in hired, you you've wondering a the think place, how just detail you give and around expanded And recently sales diagnosis thanks. specifically and that more qualitatively treatment the could folks a with if just about decisions? then affairs I and us many given both bit follow-up, physicians have of that helping you marketing in leadership and so in the have

market around I interviews looking commercially the process, a mean, of current been live of company COVID the a seen and you the the on of the start. well, part that flying one-on-one that fact company. would lot Yes, the Probably raised environment people company. I've aren't and the lot especially this - the I'll most the on are of I exciting that seen doing put newly the one globe has people at this is with things from us the have in brought running that driven of and we've commercial into both sort external excitement and commercially fact

resumes The the followership experience. comes that. Rheumatology But little and I've XX we're cases so orientation are worked of majority to from has experienced deeply that of mean, on, on these element people from we're, been recruit able majority far. deep there's seen in So a highly and come years area of decades folks, deeper that last of are some the a to biologic they've XX hired in there's or more of an in or the I and huge Max just deep percentage around scientific a that Max of myself from in does Many these and the for nephrology. or what more.

this haven't sort of or my days. since I to commercial MedImmune either like my So I a over can't that. AstraZeneca ramp seen emphasize

exciting. it's So

an question, And to as the some people to up as early to of at affairs change first in trying And able our disease The call look at trying going and think, areas pertains how hang to other work. side approved. really your the rep to the medical course part the course drug I if we're identification want to lead here the everything I folks to I it used the starts to it's of patient that really change of most got of get that's, important. launch day, this physicians first are and that word on the the be aspiration we're of managed try on and our to get do with we've the how educate I drug

as little we and what to aspirational You that to challenge identify can in right the system and getting And patient the challenge physicians the that can and and a as you're for bit fruit intend or go low you the broad his mind, possible. ensure go do. wide hanging that's physician

earlier, terms pretty done work on said But Now, our a be that. we've of we've a are And trials going in done part that. as label the to that. have part access open will we wide I of the of research be

I'm Max, just we I because this doing activity think him of reinforce And going if up to we're that give he's of aren't to some to, going to about some and Maxwell, probably question push probably everything can maybe to the the diagnostics, good I we working on know this. point, Max?

I the not Yes, are KOLs. clearly of about from in would whether or that in intervention SLE think from types add treatment it and heard even treatment. Physicians standpoint, satisfied to and this And the a it from with the research. a thanks. through matters achieve We've patient standard Thanks, not patients. delays early diagnostic clearly to Peter. for you from comments care frankly, heard they LN going also We've market these this from being in standpoint, outcomes of that market. Peter's a satisfied diagnosed from a Yes, and is

foundation down experienced, the it's standing long clinical acumen, to going boil relationships, really effective going really boil education, boil to to, with to tenured folks that really, on So it's the, promotion. down of, deep, down to going it's and and to

in of, ourselves so, change that's setting terms fostering for what the And practices. up we're and in current

that's Thank helpful. you. Okay,

approach relates The you're I it perhaps early, may realized be approaches but detail to other this discussions, may if Thanks. types to the was, I that the had wondering approval, taking partnerships? that just question still and would give you bit there be more some ex-U.S. as post parties in substantive engage of - prefer a potential that around any could

on you the analog few north Yes, the being where at focus market and strategically the U.S. opportunity, the the I of that largest can US from mean, context, as that's for we've we one product a want look of products quite and to come company take a even XX% and overall listed is building said, sales

that most to build for focus is the build of in and investment the should long-term value get drive the this intense the the company. and area going for investors and out shareholder company get the the the So, is should

both everything's fully long be global and being And outside this just done of the today, you to we've most done predict of of And timing concluded the COVID. processes scale U.S. expectations and companies, at be sort the regional we with while give us stage. to helping drug. a a the for can't predict standing to when terms obviously, a then or concrete set, concluded conversations really companies, are to internal the want can when good that ones situation, marketing their better The being progress. have in fully to biggest terms can't of we much in and on many talked selling harder when, basically and of in you those we're about to number served terms Pharma but who guided infrastructure, remotely feel of being and are get phone and these this how not we've partner computer diligence our relationships reasons. So being when we and have we impacted. would size of going the moved I with deal get have out on that and I've this, update

the guess can we get So so stay And it's still it. feel tuned. us say deal a And don't done. very goal I we comfortable, can I a it's to for see all year, ongoing,

Great, thanks, Peter. I appreciate it.

Thank you.

Thank you.

from your next comes Leerink. with question with Joseph Our question. proceed Please Schwartz SVB

the that the you do putting effective much. to resources you progress. can that in was be? LN you're I landscape structured wondering How place think force if about very how and can the, positioned your on thanks Congrats patients. cover Great, the talk is field of all treaters, for

sort as if There's going situation being as today just patients because back lapses how and we're space, with Neil relationship our under main fettered lot patients And COVID on of especially from and where it's would well. I don't think will our calling is as the will mean, question. do to the situation and have everyone, at the is obviously, population. evolving really this on I comment and, of say has access, care, between open will in we sort case full to, how whether comments that's then or rheumatologists. have But be and And, of trial just to et best give we here hearing how all don't I et this we virtual Yes, do is we're any and and hearing will to think I else major drug think cetera the et hybrid two have which but well, a a more market office-by-office, a how patient on everybody any doctor get lockdown impacts feet. good we specialties but actually in. you everything reality interactions, locked nephrologists we it to, go as down cetera. think patient two, very in might obviously, what product pandemic the the is January, to looking launch as actually are being as and any our like a you from and regional depending physicians launch just cetera? state-by-state, we're in sites physicians is by this cetera - a not seen had for maybe to that or about while you from, and smart and prepared that, in tell which access include serious face-to-face the team population see differences question situation be is is of a treatment a would a still I'll Max we to around can in we on access you're that Max planning promotion he the pandemic, terms Neil, open I what learning et assumptions on lapses see. we can and around this and be by they're sick wide think I I And on turn completely comment

site I is or hospitals able mean, up time because better use I less be the they're is as think, remotely communications. than with getting people have tied most virtual are part, good the work been to a stuff that guess access to to their in for I more physically

forward, very that and come. mean helps existing Aurinia that groups with range as but nothing And relationships that I opinion call of certainly now broad helps aa communications very, as leads. things with think a the helps one strong have moving to pre the the access of I very well the the

don't Pete As things the to we'll but how be moment we said, that matter. to at have see seem in compromised, go,

to and practices And add by this attention to training. And, paying of in to force continues engagement course, we're we're factor what success our close fundamental be of during we frankly, adapting very the do therapeutics our in thanks. successful terms that terms launching the launches would today. best Yes, and sales beyond is We're our time. I of force. what sales adapting also adapting above We're

go firmly we're to said, what we the else. key along exactly with going sales what building we're we that's And learning believe to But as that's success. be our to. is everybody As Peter that force what

Thanks added information. for the

Joe. Thanks,

Thank you.

with question Our proceed question. your next comes Company. from with Please Justin Kim Oppenheimer and

I progress. the selections high XQ, afternoon bit readout Hi, help little through anticipated and audio the on on on results can in have the level, program? just and on don't everyone, generally what would good trial for but end, a the types many all congrats too my you questions just maybe passcode talk dose inform a through of future design

simplify this I that answer. over so Yes, don't

directional comment a hope decision the see on we in me right to of dose maybe trial. on making the terms next Neil to Let ask from what

any efficacy to right dose and balance looking ranging we're of study, I the tolerability. think with

label other for drives is that in the with corneal course been highest as endpoints But formulation in used and extremely endpoint improvement the that to very with data we [indiscernible] outcomes that's seem Schirmer tolerated. the a is good [indiscernible] hemostasis. of the obviously test purchase approve [indiscernible] study of concentration and visits Although our in have consistent we calcineurin primary We the - of inhibitors because also to study, Tear from well. terms tried the good which signal see on staining, Zodra

endpoints symptoms And built Tear pre which where in into very we test to see her take, terms going for scores, is good of joints, move also our corneal lies. the our of one it which And but so specified hierarchical forward. stain, ideal I be also, example, to good would like think is results, combination Schirmer efficacy

hope we know, our is is we did in example, the the for low So, but very, that's visible how very trial. in efficacy concentration, don't for less the

based forward? some P&L of in front. R&D SG&A, And think supply expenses the activities on how wondering been and helpful. for that, modeling reflected on spend then commercial XQ just just about really the precommercialization a have potential that's the of going for seems Okay, It we question maybe production should

do yet much reasons. around a on We want try that. to haven't Maybe But, on little him for guidance you Joe, this answer a tap of a directional to given this number bit? give

we Peter. out kind say Thanks, sure. Yes, to mentioned, directionally we would continue infrastructure. as of the build I

expect increase cost the So throughout of we accordingly, will burned as it fully one remainder come would to quarter-over-quarter. the year

are clinical and There's toward some still of some we towards ongoing. shift approval trials from kind have trial R&D we related a costs, away obviously been look in the NDA/submission of obviously, costs. As towards of R&D expenses, somewhat that

back move year. of we this As the through half

into at that we're evaluating think outer years. look Obviously, shift will other, I continue. point. We the this indications

flat R&D a a it's say the say, will spend happen compared would to and look, more of with again, the I of kind what out the we of this to shift year, probably in tough actual fairly as it'll in the So remaining itself. be little years. than nature spend

yes, some far expensing As in there through as past. the obviously inventory R&D that of cost, was ran inventory

from will into look into related we shift goods of those R&D obviously As cost the expenditures future, sold.

going add forward and board I that we to gain obviously, thing with infrastructure forward. say, would our I going looks look that other to launch, and directional have the give to brought would like or here's And R&D try we to thing today. eminent on on a to and guidance the be reps approval, come voclosporin and other what will the sales mention the many how I front, us approval is how we've what last obviously our guess it's just an like, on here's on some guess here's I infrastructure and

speculative going there. be prior other only forward. we be pipeline line thing. amount our But have in It'll investing we to limited we're goal companies drugs to it's R&D past, I’ve important as a pipeline. is the that company of If be, diversify And until of sort to our continue just the think continue do in to a focused to be we the move of diversify I to as that, and, this. voclosporin, as going development to Our on won't is the said goal in be to look it's we

Okay, great.

with of what the that next last first just was had in European towards correct? still of question, progress Is was and I that a maybe wondering Just filing, half checked year. think, last the time terms guidance, I by

MDA, out EMA. in probably But we need we're trying there we thinking Japan for a of bit a somewhere FDA are work now with Yes, is the work we to filing, six we've and our U.S. as you in added the and said, extra with behind where provide months the right FDA the nine schedule a the there to for ongoing have this with of to to bit we on six meeting said, could range terms I when like little current try more situation it. six to three buffer to on to month when will months pandemic previously there. we more the work And in on for of just look nine range that Japan think then still and where target our little get we had the a and be

so Thanks much. Great.

you. Thank

you. Thank

from of Jefferies. comes Maury question your with question. line Raycroft next Our the with proceed Please

try by year one everyone, Hi, should for congrats I for the be like extension extension thanks seems AURORA I'll data this study. the you It on quick, and taking double year blind have year. questions. my progress the wondering was end to to

wondering if the of the are reporting And or year, plans so I'm disclosure? just planning this at you're on end there for what that

this around or you bat Neil to want me… do you want

actually, mean, extension year Maury. it's a I Yes. two

results So end the will year. results for that of next final till the be the available not

in I can on theoretically could then work question of voclosporin. say lot you guess, was I you And okay. a additional it, that different with Got pursue other the had just indications proteinuric It indications. you're if have you the while choosing a what indications are And on that of that's to to study? main considerations if focused some the pursue? indication new which be program, one basket going for or could on

Neil, take want you do this? to

launch I'll to space clinically we study touch first. the plans recruit little the other is and use we the the end physicians, yes, straightforward. the label drug also or to a of of where pandemic that's take during in off Actually, potential in viability, able physician prescribing but meaningful this There's of the only when a the it's to want the commercial yes. And, especially be perspective results at the were more work not also Sure, be to into the commercial, ease looking CNIs day. is, still potential going to we do disease. bit competitors and it considerations a , or What from as to at would

a think, got we basket those I especially So, there's potential And the our that to we think, or you're all some we've and that. we We're the about progress. believe will considerations. learn which we the enough on to of in end deep do right, know exclusive But just can diseases, physician community, update to kinds these study drug indications more thoughts, have but more many potentially that and dive. we of towards where of may a into this one doing you go indications, year about also,

that here. our right and from decision make input also to key the our get we're leader sure to have commercial We colleagues opinion making

taking Thanks helpful. questions. That's for my it. Got

Thanks Maury.

Thank you.

Ha the from BTIG. question. question next Please with Our from Dae your comes of Gon line proceed

my Great. Good the congrats for progress. taking and afternoon. questions all on Thanks

pre-commercialization work work that's that's on. the You've out laid on, going going been commercial the

frequent in helping telemedicine on your are to access follow-up. a So the efforts. and was recognizing ways, we just that, visits should paywalls, pre-commercialization kind I dynamic the anticipating, time, ahead, backdrop based commercial a got guess, of as COVID-XX, launch current or what seems of some of looking the a and I've that guys virtual be doctor strategy you other think the about kind and fact wondering and but are the ramp your in with at interactions same I how not

I'm mean, one this take Max. to I going for Yes,

we sort we're the we shape said, All look an right a stage on to revenue to curve a have the we're get don't understand of not don't I our working start price. we've and we, yet. all general. numbers We But right have approval, situation what As mean, end, have in now, year more to help closer a COVID have of don't what are. are aside, we're label at will folks approval, is like that a now expectations and our we on guiding as specific but potential drug, going we don't the

we our time. roll all that well right Max this drug the at as that our really make We said transcripts. out So to do and we Know want his for we are aspirations though, to but notes sure as and come that we for with want investors the in company and a to growth, want of approval people patients for very closer and to successful the the get surprise launch to at end more potential and year.

and Great toward AUDREY, disease. eye look for quickly, implications real has development we and as future dry just AUDREY your obviously

own in mentioned the Just maybe wondering, a of same you in while concurrently start you terms plan commercializing that but time, previously your a at even and working could partnership. on you'll for partner on ophthalmology, looking be your commercial

Is terms kind X, or have and So when “timeline” mind of there you AUDREY of you just partnership, that of us X, the after is in if that you reminding before considerations currently want wouldn't sort you're for that Phase your it thing? looking in data? a

market we'd all we've We to see ears the someone terms sure the in want be process, investors be if of to have and this come to and to in can a That involved little said, the involved way through, open on rare really fund that's side so made us a were so, think this I in the we assumption. thing sort sort to through get say I autoimmune like process our fully I you'd deal with LN, to do regulatory to now of being of try and, and something more did our that things, regulatory will acute even we dictate two focus But core phone. a the really to in co-development, expected think think are on Well, in somewhat stay smart talk a one renal renal of the done. disease bit us is when process, will like plans, in diseases that think of that timing That as to we a ability much for then drug a than that global couldn't other is It commercially in is level cases think diagnosed, have dry different we these would care firm But pharmacy, ideal primarily I higher patients a and is company see they play. And physician, ophthalmology there. care a then eye we a ophthalmologist necessarily have eye is types a that small have competitive, disease it's if the way company diseases mean we dry lot and crosses great before figure believers some primary out invest hand a the and of many burden an take We're doesn't and partner looks around multispecialty. would. a have get that path even see launch an see even like to after. they and of don't ways the launch they the and drug. of to at a deeper pockets the that

partner in the but nephritis, now lupus and ways great Ophthalmology autoimmune is because strategically launch to disease, we launch the we side, the think get a a approach. a ability a but an go miss think to kidney, that we be size this the it probably I the et marketing, there in could of where it spend direct-to-consumer to said, won't great molecule have has focus and cetera, bolt-on if like. will would ongoing. we situation to look other space our probably in to infrastructure are opportunity being that get where have timing potentially targeted has approval, and and is to of we do the primary that a better and drug So well is do have, ability on money terms we partner and right this that caught on we as But the

Great. our taking questions. Thanks for

Thank you.

Thank you.

Doug question. proceed with Our Please next RBC of question Markets. comes from Miehm the line Capital with your

Good afternoon.

be you negative do that you label. care sort go on you are which Just I be, of times of based then, terms patients that what us us the into opinion? of you that what call, single you quality terms to And label maybe the the label its what think could Peter, your in a at the And currently tie me. couple in the it of mentioned and your data optimal not are important that's provide could on in it could of Thanks. be standard of but could perhaps that, importance, this? you've from generating, question through of with think the that If could would if which the bookends question do on do asked has this that'd what helpful? with walk beginning an was, a you're

a is to always generalities on the when of God, you going like one this need because ask question what then know and best a little oh case, you mean, Yes, the your the bit on, to scenarios. middle worse we're I Agency. I'm talking help it's difficult I'll in

to of short in ability want hope. I they're look of need what company to a try sort And patience those our to they the is dialogue. a conversations of transplant day, think area or to start becomes studied. have those be for it labels answer of pegging could But they're at should our know is when patient at are really but, what that to good probably be in I the at you wouldn't the much to that I cetera, looked they what and pretty would pretty the there. been you that duration label ability sort afforded label nephritis, those here's are and, And terms I brought for it’s maybe what's the with to a that wouldn’t to not lupus et our how to lead written and, we're and be have the studied active treat but of worst to hope drug. able open written widely like So have conversations a expectations the anything is say be the terms focuses so use that in poison label, not question think probably lot clinical be the warnings of to CNIs of long on more of we've the the to and a appropriate on always precautions where area appropriate in help population, drug color around area treatment in the scenario end how warnings we where, is, limiting have case we're allowed, complex would the

patients has of Here's for populations, approved we're that first, since to is to we're only be et to hope to be And these patient to And we our go expectation avoid. first, as patients where, want can, should we opinion, have, trying It's be as the what that symptoms we approach first The should areas, It's And, of really in to answer This the fine. studied. agency will contraindications to in as just may here, the be. measured, go ensure just very drug pitfalls should patient even to diagnostic and to hopefully they bottom-line. And not try been are wide obviously. potentially cetera. limited patients Those that got since the we things, physician terms like we really expect, allow get the studied that, would looking disease. contraindications, go benefit silent doing continues maybe back a really I'll be those happen. as can, we it's important, patients patients fine, that they're that far to not there, of previous change are aspirational. the the that are are wouldn't that of at not there complaining that to be Patients this. ensure truly are doing ensure coming that to out proteinuric to and here. is if with are and appropriate, But challenging be standard that that

you. with the technical can that Neil, I a to on aspirational think we we get it's hope So but best more wide there, lot but go. our with in just say don't ongoing our interest answered to hopefully I be anything, we for how if negotiations FDA

Thank you.

of reached the end session. have We our question-and-answer

the floor back for Greenleaf over comments. So any Mr. I'd like to to pass closing additional

with us week great a with of ride this I thank want the us. day. and your a time for continuing end have great evening. the everybody take Have taking all I for hope thanks you to to

you Once your teleconference webcast. for you disconnect conclude lines this time. at today's may again, Ladies does and and thank and we gentlemen, participation this your